{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:59:08Z","timestamp":1783130348966,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T00:00:00Z","timestamp":1344470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s13277-012-0471-7","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T03:48:09Z","timestamp":1344397689000},"page":"2117-2123","source":"Crossref","is-referenced-by-count":55,"title":["Does HE4 have a role as biomarker in the recurrence of ovarian cancer?"],"prefix":"10.1007","volume":"33","author":[{"given":"Francesco","family":"Plotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Aloisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Benedetti-Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,9]]},"reference":[{"issue":"1","key":"471_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"APM Heintz","year":"2006","unstructured":"Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS, Pecorelli S. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int j gynaecol obstet off organ Int Fed Gynaecol Obstet. 2006;95(1):161\u201392.","journal-title":"Int j gynaecol obstet off organ Int Fed Gynaecol Obstet"},{"issue":"12","key":"471_CR2","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.25203","volume":"116","author":"RC Bast Jr","year":"2010","unstructured":"Bast Jr RC. CA125 and the detection of recurrent ovarian cancer. Cancer. 2010;116(12):2850\u20133.","journal-title":"Cancer"},{"issue":"4","key":"471_CR3","first-page":"511","volume":"79","author":"S Grover","year":"1992","unstructured":"Grover S, Quinn MA, Weideman P, Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol. 1992;79(4):511\u20134.","journal-title":"Obstet Gynecol"},{"key":"471_CR4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374\u201382.","journal-title":"Gynecol Oncol"},{"key":"471_CR5","first-page":"3695","volume":"63","author":"I Hellstr\u00f6m","year":"2003","unstructured":"Hellstr\u00f6m I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstr\u00f6m KE. The HE4 [WFDC2] protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695\u2013700.","journal-title":"Cancer Res"},{"key":"471_CR6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast Jr RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402\u20138.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"471_CR7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1530\/ror.0.0030086","volume":"3","author":"C Kirchhoff","year":"1998","unstructured":"Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3(2):86\u201395. Review.","journal-title":"Rev Reprod"},{"key":"471_CR8","unstructured":"Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010;11(1):111\u20136."},{"key":"471_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2011.01.014","volume":"121","author":"ND Fleming","year":"2011","unstructured":"Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:249\u201352.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"471_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","volume":"31","author":"E Anastasi","year":"2010","unstructured":"Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010;31(2):113\u20139.","journal-title":"Tumor Biol"},{"key":"471_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","volume":"7","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361\u20134.","journal-title":"Ann Oncol"},{"key":"471_CR12","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","volume":"19","author":"GJ Rustin","year":"2001","unstructured":"Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054\u20137.","journal-title":"J Clin Oncol"},{"issue":"9747","key":"471_CR13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","volume":"376","author":"GJ Rustin","year":"2010","unstructured":"Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155\u201363.","journal-title":"Lancet"},{"issue":"1","key":"471_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","volume":"4","author":"I Jacobs","year":"1989","unstructured":"Jacobs I, Bast Jr RC. The CA125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1\u201312.","journal-title":"Hum Reprod"},{"issue":"7","key":"471_CR15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-05-2007","volume":"12","author":"N Scholler","year":"2006","unstructured":"Scholler N, Crawford M, Sato A, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006;12(7):2117\u201324.","journal-title":"Clin Cancer Res"},{"key":"471_CR16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-0-387-68969-2_2","volume":"622","author":"I Hellstrom","year":"2008","unstructured":"Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and\/or each other. Adv Exp Med Biol. 2008;622:15\u201321.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"471_CR17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/IGC.0b013e31821bb88c","volume":"21","author":"SM Geurts","year":"2011","unstructured":"Geurts SM, de Vegt F, van Altena AM, van Dijck JA, Tjan-Heijnen VC, Verbeek AL, Massuger LF. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011;21(5):837\u201345.","journal-title":"Int J Gynecol Cancer"},{"key":"471_CR18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajog.2010.03.043","volume":"203","author":"RG Moore","year":"2010","unstructured":"Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228\u201333.","journal-title":"Am J Obstet Gynecol"},{"key":"471_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","volume":"23","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S, Franchi M, Guidi GC. The utility of serum human epididymis protein 4 [HE4] in patients with a pelvic mass. J Clin Lab Anal. 2009;23:331\u20135.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"471_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","volume":"121","author":"F Jacob","year":"2011","unstructured":"Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D, Heinzelmann-Schwarz V. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121(3):487\u201391.","journal-title":"Gynecol Oncol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-012-0471-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0471-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:24:44Z","timestamp":1559489084000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-012-0471-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,9]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s13277-012-0471-7","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,9]]}}}